EGFR and non-small cell lung carcinoma: The National Comprehensive Cancer Network NSCLC Panel recommends osimertinib as a preferred first-line therapy option for patients with metastatic NSCLC who have sensitizing EGFR mutations based on a phase 3 trial and FDA approval.